Category: Wall Street BeatSyndicate content

Vital Therapies aims even lower with $12-per-share IPO | MassDevice.com On Call

April 18, 2014 by Arezu Sarvestani

Bio-artificial liver maker Vital Therapies takes its IPO even lower, now planning to open at $12 per share.

MassDevice.com On Call

MASSDEVICE ON CALL — California biotherapeutics company Vital Therapies dropped its per-share price even lower, opening today at $12 per share in the hopes of raising $54 million. Shares are slated to open today on the Nasdaq market under the symbol "VTL."

Cardiac Dimensions closes $20M equity round

April 17, 2014 by Brad Perriello

Cardiac Dimensions raises $20 million from a syndicate of international investors for its Carillon mitral valve implant.

Cardiac Dimensions closes $20M equity round

Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.

M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, according to a press release. Investors in Australia, the U.S. and Canada also participated, the company said.

Mainstay Medical readies European IPO

April 17, 2014 by Brad Perriello

Mainstay Medical looks to raise up to $42 million with an initial public offering on the EuroNext stock exchange.

Mainstay Medical readies European IPO

Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.

Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.

Baxter blows away Wall Street as renal sales surge in Q1

April 17, 2014 by Arezu Sarvestani

Baxter International's medical products division gets a major boost in the company's 1st quarter, pushing adjusted per-share earnings 9¢ above expectations.

Baxter blows away Wall Street with dialysis sales surge in Q1

Illinois healthcare titan Baxter (NYSE:BAX) isn't getting much Wall Street love today after posting Q1 adjusted per-share earnings that blew away expectations.

GE Healthcare's Q1 sales, profits slide

April 17, 2014 by Brad Perriello

Sales and profits were down during the 1st quarter for GE Healthcare, which cited "market volatility" for the declines.

keys: ge healthcare, general electric, earnings

GE Healthcare's Q1 sales, profits slide

GE Healthcare (NYSE:GE) saw its sales and profits decline by single digits during the 1st quarter due to "market volatility.

Ex-Stryker exec dodges jail in insider trading scheme

April 17, 2014 by Brad Perriello

Former Stryker executive Mark Foldy, who pleaded guilty last year for his part in an insider trading scheme, dodges a jail sentence.

Ex-Stryker exec dodges jail in insider trading scheme

A former Stryker (NYSE:SYK) marketing executive escaped a jail sentence yesterday, instead drawing 6 months of home confinement and 2 years of probation for passing along inside information ahead of Stryker's 2011 acquisition of Orthovita.

Vital Therapies prices $54M IPO

April 17, 2014 by Brad Perriello

Vital Therapies once again lowers the bar on its initial public offering, pricing the flotation at $12 per share.

Vital Therapies prices $54M IPO

Vital Therapies priced its initial public offering at $12 per share, once again lowering the bar for its 1st public flotation after scuttling its 1st try at a U.S. IPO.

Vital Therapies, which is developing a bio-artificial liver, last October set the IPO's price range at $16-$18. But the San Diego-based company but shelved the offering until March, when it set the range at $13-$15 per share.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp